Showing posts with label aids. Show all posts
Showing posts with label aids. Show all posts

Sunday, 1 January 2017

50 Facts on HIV/AIDS

50 Facts on HIV/AIDS

Dr KK Aggarwal
National President IMA



1.     AIDS is caused by the human immunodeficiency virus (HIV), which damages the immune system, lowering the resistance of the body to fight off infections.
2.     AIDS is the advanced stage (stage 4) of HIV infection.
3.     Progression from HIV infection to AIDS, if untreated, may take 8-10 years. In young children, it usually develops much faster.
4.     HIV-positive people may remain asymptomatic but can still pass on the virus to others.
5.     78 million (69.5 million–87.6 million) people have become infected with HIV since the start of the epidemic (end 2015).
6.     35 million (29.6 million–40.8 million) people have died from AIDS-related illnesses since the start of the epidemic (end 2015).
7.     36.7 million (34.0 million–39.8 million) people globally were living with HIV (end 2015).
8.     1.1 million (940 000–1.3 million) people died from AIDS-related illnesses (end 2015).
9.     2.1 million (1.8 million–2.4 million) people became newly infected with HIV (end 2015).
10.  18.2 million (16.1 million–19.0 million) people were accessing antiretroviral therapy (June 2016)
11.  People with HIV are at risk of developing active TB disease.
12.  Transmission of HIV/AIDS can be prevented.
13.  HIV spreads through unprotected sex with an HIV–positive person.
14.  HIV spreads through transfusions of unscreened (HIV–positive) blood.
15.  HIV can spread from an infected woman to her child during pregnancy and childbirth.
16.  HIV infection can be passed from a mother to her child through breastfeeding.
17.  HIV spreads by unsterilized infected needles or syringes, especially those used for injecting drugs.
18.  Used infected razor blades, knives or tools that cut or pierce the skin also carry some risk of spreading HIV.
19.  Touching, hugging, shaking hands, coughing and sneezing will not spread the virus.
20.  HIV/AIDS cannot be transmitted through toilet seats, telephones, plates, glasses, eating utensils, towels, bed linen, swimming pools or public baths.
21.  Up to 70 % of partners of people with HIV are also HIV positive.
22.  Practicing safe sexual behaviors such as using condoms prevents HIV transmission.
23.  All pregnant mothers should get HIV test done.
24.  A blood test is the most accurate way to tell if someone is infected with HIV.
25.  Most tests for HIV/AIDS check for the presence of antibodies to the virus.
26.  If the result of an HIV/AIDS test is negative, this means the person tested is not infected or it is too early to detect the virus.
27.  Infection may not be detected up to the first few weeks to few months.
28.  Even if the first test is negative, the test should be repeated 6 months after any possible exposure to HIV infection.
29.  The time period when an infected person does not test as HIV positive is called ‘window period’.
30.  All people, including children, are at risk for HIV/AIDS, including occupational risk.
31.  People who have a sexually transmitted infection (STI) are at greater risk of getting HIV and of spreading HIV to others.
32.  Persons suffering from STIs have a 5–10 times higher risk of becoming infected with HIV if they have unprotected sexual intercourse with an HIV–infected person.
33.  If both partners are not treated for a STI, they will continue infecting each other with the sexually transmitted infection.
34.  The more sex partners people have, the greater the risk that one of them will have HIV/AIDS and pass it on.
35.  Antiretroviral therapy (ART) should be started at the earliest to prevent HIV transmission to sexual or drug using partner/s or from the mother to the infant during pregnancy or breastfeeding.
36.  People with STIs should seek prompt treatment and avoid sexual intercourse or practice safe sex.
37.  Men with HIV are less likely to be diagnosed and put on ART and are more likely to die of HIV-related causes than women.
38.  Internal secretions, which can harbor HIV virus, are blood (including menstrual blood, semen, vaginal secretions, breast milk, peritoneal fluid, brain fluid, pleural lung fluid, pericardial heart fluid etc. These secretions, when mixed with secretions of another person infected with HIV transmit HIV.
39.  External secretions, which do not harbor the HIV virus are saliva, tear, sweat, urine and feces. The mixing of these secretions with secretions of an HIV-positive person does not transmit HIV.
40.  HIV does not spread by mosquitoes or other insects.
41.  HIV counseling and testing can help in the early detection of HIV infection, to get the support services for those who are infected.
42.  Counseling helps to manage other infectious diseases they might have, and learn about living with HIV/AIDS and how to avoid infecting others.
43.  Counseling and testing can also help those not infected to remain uninfected through education about safer sex.
44.  Pre-exposure prophylaxis with tenofovir-emtricitabine in high risk patients and who are committed to medication adherence and close follow-up can reduce the risk of HIV infection by 48 to 75%.
45.  Drinking alcohol or taking drugs interferes with judgment. Even those who understand the risks of AIDS and the importance of safer sex may become careless after drinking or using drugs.
46.  Young people need to be educated that there is no vaccination and no cure for HIV/AIDS.
47.  WHO recommends innovative HIV-self-testing and partner notification approaches to increase HIV testing services among undiagnosed people.
48.  Prevention is the only protection against HIV/AIDS.
49.  ABC for safe sex: Abstain, Be faithful to your partner and if you cannot, use Condoms.

50.  90–90–90 is a treatment target to help end the AIDS epidemic. By 2020, 90% of all people living with HIV will know their HIV status; 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy and 90% of all people receiving antiretroviral therapy will have viral suppression.

Friday, 22 July 2016

IMA & HCFI stand for AIDS control and hold a webcast on the latest innovations in the prevention, treatment and care regime

IMA & HCFI stand for AIDS control and hold a webcast on the latest innovations in the prevention, treatment and care regime New Delhi, 21st July, 2016: As per India HIV estimation 2015 report, there are nearly 21 lakhs HIV positive people in our country out of which a huge population is not even aware of their condition. These appalling figures substantiate the fact that India has the third largest number of people living with HIV in the world. In India, the prevalence of HIV positive among pregnant ladies is 0.11%, 2% among commercial female sex workers (FSW), 4% among male sex workers (MSW) and 11% among Intravenous drug users. The need for raising awareness about the available diagnostic procedures and the treatments for AIDS is a matter of prime importance in our country. Stressing on the urgent need to eliminate the social stigma around the disease, the IMA and Heart Care Foundation of India organised a webcast today. The expert faculty for the same consisted of Dr P S Nayyer, Consultant Physician, BSAH, Former Addl, Project Director, Delhi State AIDS Control Society, Dr. VK Monga, Dean, IMA CGPand Padma Shri Awardee Dr KK Aggarwal – President HCFI & Honorary Secretary General IMA. Speaking about the same, Padma Shri Awardee Dr KK Aggarwal – President HCFI & Honorary Secretary General IMA said, "Not many people are aware that the diagnosis and treatment of HIV positive patients are free in India. One can just walk into any Govt. centre and get herself/himself checked. Now when someone is diagnosed with Tuberculosis, it has become advisable to get him/her tested for HIV too. It is true vice versa. Earlier the better is what is being practiced in the HIV treatment module now. Earlier people used to wait for the symptoms to appear but now action is taken fast so as to bring more and more number of HIV patients under treatment. Healthcare workers if struck by any needle injury and all rape victims should undergo Post-exposure prophylaxis (PEP). Those who indulge in high risk sexual activity and do not want to take protection should undergo PEP on a continuous basis.” Adding to this, Dr P S Nayyer, Consultant Physician, BSAH, Former Addl, Project Director, Delhi State AIDA Control Society said, ”The diagnosis of AIDS cannot be based on a single test. If one test is positive, repeat tests need to be done. Safe sexual practices and safe blood transfusion are the key. For Intravenous drug users, safe needle exchange programmes are there which entail single use and safe needle practice. There has been lot of advancements in the Antenatal and perinatal strategies to prevent mother-to-child transmission of HIV infection. It should be known that mother-to-child HIV transmission is 100% controllable, preventable and curable. HIV should not be considered a stigma. It is a chronic manageable disease like Hepatitis B and C. In terms of transmission, Hepatitis B virus is more transmissible than HIV. Hepatitis C now is curable and thus, there is a hope that HIV will also be curable. ” A few points discussed in the webcast include 1. India has nearly 21 lakh HIV positive patients 2. Diagnosis and treatment of AIDS are free in India 3. Earlier the better is the new mantra for HIV treatment 4. Diagnosis is not based on a single test. If 1 test is +ve, repeat tests need to be done. 5. Safe sexual practice is the key 6. Mother to child HIV transmission is 100% preventable, controllable and curable 7. HIV is no more a stigma; it is a chronic manageable disease like Hepatitis B and C 8. Hepatitis C is now curable and there is hope that AIDS too will also be curable

Saturday, 16 July 2016

Updated HIV guidelines integrate treatment and prevention

Updated HIV guidelines integrate treatment and prevention

Dr K K Aggarwal

The International Antiviral Society-USA panel on antiretroviral (ARV) drug therapy for HIV infection has released updated recommendations, which for the first time, have integrated treatment and prevention. The guidelines say that ARVs remain the cornerstone of HIV treatment and prevention and when used effectively, currently available ARVs can sustain HIV suppression and can prevent new HIV infection. The guidelines “Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults2016 Recommendations of the International Antiviral Society–USA Panel” are published July 12, 2016 in JAMA. Some key recommendations are: • Antiretroviral therapy (ART) should be started in all individuals with HIV infection with detectable viremia regardless of CD4 cell count. • The recommended optimal initial regimens include an integrase strand transfer inhibitor (InSTI) + 2 nucleoside reverse transcriptase inhibitors (NRTIs). Other effective regimens include nonnucleoside reverse transcriptase inhibitors or boosted protease inhibitors with 2 NRTIs. • ART should be started within the first 2 weeks after diagnosis for most acute opportunistic infections, with the possible exception of acute cryptococcal meningitis. • Reasons for switching therapy include convenience, tolerability, simplification, anticipation of potential new drug interactions, pregnancy or plans for pregnancy, elimination of food restrictions, virologic failure, or drug toxicities. • Laboratory assessments are recommended before treatment, and monitoring during treatment is recommended to assess response, adverse effects, and adherence. If ART is being initiated on the first clinic visit, all laboratory specimens should be drawn prior to the first dose of ART; resistance testing results should be used to modify the regimen as necessary. Recommended pre-ART tests include CD4 cell count, plasma HIV-1 RNA, serologies for hepatitis A, B, and C, serum chemistries, estimated creatinine clearance rate, complete blood cell count, urine glucose and protein, sexually transmitted infection screening, and fasting lipid profile. Genotypic testing for reverse transcriptase and protease resistance mutations is also recommended pre-ART. • Systematic monitoring of time to care linkage following initial HIV diagnosis, retention in care, ART adherence, and rates of viral suppression is recommended in all care settings. • Preexposure prophylaxis should be considered as part of an HIV prevention strategy for at-risk individuals. Daily, rather than intermittent, tenofovir disoproxil fumarate/emtricitabine is the recommended PrEP regimen. Detailed sexual, substance use, and medical histories are important for deciding whether to provide PrEP. • The guidelines recommend vaccination against hepatitis A and hepatitis B for those who are not immune and human papillomavirus vaccination. • Postexposure prophylaxis is recommended as soon as possible after exposure without waiting for confirmation of HIV serostatus of the source patient or results of HIV RNA or resistance testing. Postexposure prophylaxis regimens should be continued for 28 days, and HIV serostatus should be reassessed at 4 to 6 weeks, 3 months, and 6 months after exposure.